Cancer immunology, immunotherapy : CII
Journal
Overview
publication venue for
-
Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
2005
-
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.
2023
-
The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.
2023
-
Personalized tumor vaccine for pancreatic cancer..
72.
2022
-
Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors..
71.
2022
-
Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.
2021
-
Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.
2021
-
Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients..
70.
2021
-
Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration..
70.
2021
-
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer..
70.
2020
-
Prevention of liver metastases through perioperative acute CpG-C immune stimulation..
69.
2020
-
Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients..
68.
2019
-
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition..
68.
2019
-
Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models..
66.
2016
-
Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1..
64.
2014
-
Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study..
64.
2014
-
Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy..
63.
2014
-
CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis..
62.
2013
-
Mast cells impair the development of protective anti-tumor immunity..
61.
2012
-
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor..
61.
2011
-
CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma..
61.
2011
-
Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci..
61.
2011
-
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients..
60.
2011
-
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?.
60.
2011
-
Impact of minimal tumor burden on antibody response to vaccination..
60.
2011
-
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer..
59.
2010
-
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity..
59.
2010
-
Chordoma and chondrosarcoma gene profile: implications for immunotherapy..
58.
2008
-
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects..
57.
2008
-
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"..
56.
2007
-
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors..
57.
2007
-
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy..
56.
2007
-
Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals..
56.
2006
-
Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients..
56.
2006
-
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy..
54.
2005
-
A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation..
54.
2005
-
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer..
54.
2005
-
Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells..
54.
2005
-
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies..
51.
2002
-
Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors..
49.
2000
-
CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro..
48.
2000
-
Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line..
47.
1999
-
In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors..
47.
1999
-
Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen..
47.
1998
-
Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104..
44.
1997
-
Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors..
41.
1995
-
Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor..
41.
1995
-
Keyhole limpet hemocyanin contains Gal(beta 1-3)-GalNAc determinants that are cross-reactive with the T antigen..
40.
1995
-
Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias..
39.
1994
-
Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody..
39.
1994
-
Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes..
38.
1994
-
IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells..
36.
1993
-
Interleukin-6 and renal cell cancer: production, regulation, and growth effects..
35.
1992
-
Reactivity of a human monoclonal antibody against carcinomas and other lesions of the colon..
28.
1989
-
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
2018
-
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.
2013
-
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
2020
-
Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
2017
-
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
2011
-
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
2011
-
Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
2022
Identity
ISO Abbreviation
-
Cancer Immunol Immunother
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)